AMG 193 + Docetaxel for Advanced Solid Cancers
(MTAP Trial)
Trial Summary
What is the purpose of this trial?
This trial tests AMG 193 in adults with advanced cancers. The drug aims to specifically attack these cancer cells.
Will I have to stop taking my current medications?
The trial requires that you stop taking any prescription medications that are strong inducers of cytochrome P450 3A4 (CYP3A4) at least 14 days or 5 half-lives before starting the study. Additionally, you must not have received anti-tumor therapy within 28 days of the study start date.
What data supports the effectiveness of the drug combination AMG 193 and Docetaxel for treating advanced solid cancers?
What safety data exists for AMG 193 and Docetaxel in humans?
Docetaxel, a chemotherapy drug, is known to cause side effects like venous thrombosis (blood clots in veins) and gastrointestinal toxicity (stomach and intestine issues), especially in older patients or those with other health problems. In a study of AMG 193, some patients with advanced solid tumors experienced partial responses, but specific safety data for AMG 193 is not detailed.24678
What makes the drug combination of AMG 193 and Docetaxel unique for treating advanced solid cancers?
The combination of AMG 193, a PRMT5 inhibitor, and Docetaxel, a well-established chemotherapy drug, is unique because it targets cancer cells through different mechanisms, potentially enhancing the overall antitumor effect. This approach is novel as it combines a targeted therapy with a traditional chemotherapy agent, which may improve treatment outcomes for patients with advanced solid cancers.2591011
Eligibility Criteria
Adults over 18 with advanced solid tumors that can't be cured by surgery or radiation, specifically those without the MTAP gene. Participants must be able to take oral medication and have a life expectancy of at least 12 weeks. They should not have had certain prior treatments, active infections, heart issues, or other recent cancer therapies.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AMG 193 alone or in combination with docetaxel to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AMG 193 (Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor)
- Docetaxel (Taxane)